TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02210559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
Study: NCT01734070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry consumption
Description: Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
Study: NCT01254734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: Undergo transoral robotic microsurgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02883608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cap assisted forward-viewing endoscope
Description: a cap fitted to the to top of the forward-viewing endoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cap assisted forward-viewing endoscope
Description: a cap fitted to the to top of the forward-viewing endoscope
Study: NCT00857701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Extension Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
Study: NCT03874091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ESP block with 0,25% Bupivacaine+ Adrenaline
Description: Regional anaesthesia technique performed under ultrasound guidance before surgery
Study: NCT03431688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAM
Description: treatment with PPI, metonidazole, amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PBMT
Description: treatment with PPI, metonidazole, bismuth, tetracyclin
Study: NCT02810210

Intervention type: OTHER
Intervention: fundus examination
Description: In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups.

Intervention type: OTHER
Intervention: Head ultrasound
Description: In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups.
Study: NCT02776631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinloc
Description: Internal fixation device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hansson Pins (LIH)
Description: Internal fixation device
Study: NCT03874091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline
Description: Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
Study: NCT01460979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25mg weekly intravenous until progression
Study: NCT03397472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic field modulation device
Description: use the device with magnetic field modulation to treat insomnia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo device
Description: use the sleep pillow without magnetic field modulation treatment
Study: NCT02010099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP110 Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP110 Medicated wipes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation-H Cream
Study: NCT01858675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers, red blood cells and plasma assessment
Study: NCT00231959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole (Mirapex)
Description: pramipexole 0.5mg tablets qd and titrated per protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill
Study: NCT02233972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00614848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor drug eluting coronary stent
Description: Zotarolimus coated coronary stent (10ug/mm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor drug eluting coronary stent
Description: Zotarolimus coated coronary stent (10ug/mm)
Study: NCT02584504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study: NCT03514160

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group exercise
Description: Group exercise based on the American College of Sports Medicine guidelines.
Study: NCT01734499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Class
Description: A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT-B Quality of Life
Description: The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACT-B Quality of Life
Description: The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
Study: NCT05451758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
Study: NCT05059561

Intervention type: RADIATION
Intervention: X-ray radiograghy
Description: Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
Study: NCT00709072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS (Short Message Service) reminders
Description: SMS reminders sent every 2 weeks
Study: NCT02584504

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 5 mg tablet orally.
Study: NCT05822973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3.0 monocryl suture
Description: incision will be closed with absorbable suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3.0 nylon suture
Description: incision will be closed with non-absorbable suture
Study: NCT04226209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSSE
Description: Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
Study: NCT04116905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
Study: NCT02491463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3389245A_LD GROUP
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3389245A_HD GROUP
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Study: NCT01098266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF plus Best Investigator's Choice (BIC)
Description: * NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Best Investigator's Choice (BIC)
Description: * Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Study: NCT01883544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALXN1007
Study: NCT00891241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI 1195-101
Description: Single dose, bolus IV injection of LMI 1195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI 1195-101
Description: Single dose, bolus IV injection of LMI 1195
Study: NCT03558230

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Constraint-Induced Movement Therapy
Description: The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Constraint-Induced Movement Therapy
Description: The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
Study: NCT03829722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV once per week during radiation therapy (AUC=1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV once per week during radiation therapy (30mg/m\^2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given 5 days/week for a total of 35 doses (70 gray total).
Study: NCT01838915

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics+Glutamine
Description: Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin, 20 g.
Study: NCT03850028

Intervention type: OTHER
Group type: OTHER
Intervention: 89Zr-atezolizumab PET scans
Description: The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151).
Study: NCT04119128

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Description: Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
Study: NCT03842059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided detection
Description: We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy
Study: NCT00851279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic irrigated ablation catheter
Description: Magnetic irrigated catheter to be used with the magnetic navigation system
Study: NCT02644577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03558230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration applied to the wrist.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for vibration)
Description: No vibration applied to the wrist.
Study: NCT02644577

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Study: NCT01966289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY is administered intravenously at 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY is administered intravenously at 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY is administered intravenously at 200 mg/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110 is administered subcutaneously at 60 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110 is administered subcutaneously at 60 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110 is administered subcutaneously at 60 mg/m2
Study: NCT03642496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose ET019002- T Cells
Description: ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Middle dose ET019002- T Cells
Description: ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose ET019002- T Cells
Description: ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
Study: NCT02881762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
Study: NCT03887234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coracoclavicular ligament reconstruction
Description: Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coracoclavicular ligament reconstruction
Description: Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
Study: NCT04278976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of CoBaTrICE
Description: The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process.